Risk Factors for Recurrence Amongst High Intermediate Risk Patients with Endometrioid Adenocarcinoma

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2012 Oct 25

PMID 23094129

Citations 6

Authors

Agnes Y Bahng

Christina Chu

Paul Wileyto

Stephen Rubin

Lilie L Lin

Affiliations

Soon will be listed here.

Abstract

Objective: To determine risk factors associated with recurrence in patients with high intermediate risk (HIR) endometrioid adenocarcinoma.

Methods: A retrospective analysis of patients with HIR endometrioid adenocarcinoma who underwent hysterectomy, bilateral salpingo-oophorectomy, with or without pelvic/para-aortic lymphadenectomy at the University of Pennsylvania between 1990 and 2009 was performed.

Results: A total of 103 women with HIR endometrial cancer were identified. Multivariable analysis revealed that ≥2/3 myometrial invasion (HR, 4.79; p=0.010) and grade 3 disease (HR, 3.04; p=0.045) were independently predictive of distant metastases. The 5-year distant metastases free survival (DMFS) for patients with neither or one of these risk factors was 89%, and the 5-year DMFS for patients with both risk factors was 48% (p<0.001).

Conclusion: Patients with both grade 3 disease and deep third myometrial invasion have a high risk of distant metastases. Identifying these patients may be important in rationally selecting patients for systemic therapy.

Citing Articles

Predictors of recurrence and survival in lymphovascular space invasion negative early-stage endometrioid endometrial cancer patients.

Altin D, Akinci T, Taskin S, Ortac F J Turk Ger Gynecol Assoc. 2023; 24(4):261-270.

PMID: 38054418 PMC: 10702257. DOI: 10.4274/jtgga.galenos.2023.2022-6-11.

Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification.

Zammarrelli 3rd W, Kim S, Da Cruz Paula A, Rios-Doria E, Ehmann S, Yeoshoua E JCO Precis Oncol. 2022; 6:e2200194.

PMID: 36240474 PMC: 9616646. DOI: 10.1200/PO.22.00194.

The correlation between microRNA490-3p and TGFα in endometrial carcinoma tumorigenesis and progression.

Sun K, Chen Y, Chen S, Liu B, Feng M, Zong Z Oncotarget. 2016; 7(8):9236-49.

PMID: 26843615 PMC: 4891037. DOI: 10.18632/oncotarget.7061.

SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer.

Liu L, Zhang J, Yang X, Fang C, Xu H, Xi X PLoS One. 2015; 10(9):e0138515.

PMID: 26407074 PMC: 4583418. DOI: 10.1371/journal.pone.0138515.

A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells.

Bao W, Wang H, Tian F, He X, Qiu M, Wang J Mol Cancer. 2013; 12:155.

PMID: 24321270 PMC: 3879200. DOI: 10.1186/1476-4598-12-155.

References

Gadducci A, Cavazzana A, Cosio S, Di Cristofano C, Tana R, Fanucchi A . Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res. 2009; 29(5):1715-20. View

Mariani A, Webb M, Keeney G, Haddock M, Calori G, Podratz K . Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol. 2000; 182(6):1506-19. DOI: 10.1067/mob.2000.107335. View

Greven K, Randall M, Fanning J, Bahktar M, Duray P, Peters A . Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 1990; 19(3):529-34. DOI: 10.1016/0360-3016(90)90477-2. View

Lee C, Szabo A, Shrieve D, Macdonald O, Tward J, Skidmore T . Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer. 2007; 110(9):2092-100. DOI: 10.1002/cncr.22997. View

Keys H, Roberts J, Brunetto V, Zaino R, Spirtos N, Bloss J . A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(3):744-51. DOI: 10.1016/j.ygyno.2003.11.048. View

Chadha M, Nanavati P, Liu P, Fanning J, Jacobs A . Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol. 1999; 75(1):103-7. DOI: 10.1006/gyno.1999.5526. View

Horowitz N, Peters 3rd W, Smith M, Drescher C, Atwood M, Mate T . Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002; 99(2):235-40. DOI: 10.1016/s0029-7844(01)01672-6. View

Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P . The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease. Gynecol Oncol. 1998; 70(2):247-54. DOI: 10.1006/gyno.1998.5064. View

Ng T, Nicklin J, Perrin L, Cheuk R, Crandon A . Postoperative vaginal vault brachytherapy for node-negative Stage II (occult) endometrial carcinoma. Gynecol Oncol. 2001; 81(2):193-5. DOI: 10.1006/gyno.2001.6130. View

10.

Fotiou S, Trimble E, Papakonstantinou K, Kondi-Pafiti A, Panoskaltsis T, Deliconstantinos G . Complete pelvic lymphadenectomy in patients with clinical early, grade I and II endometrioid corpus cancer. Anticancer Res. 2009; 29(7):2781-5. View

11.

Morrow C, Bundy B, Kurman R, Creasman W, Heller P, Homesley H . Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991; 40(1):55-65. DOI: 10.1016/0090-8258(91)90086-k. View

12.

Convery P, Cantrell L, Di Santo N, Broadwater G, Modesitt S, Secord A . Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. Gynecol Oncol. 2011; 123(1):65-70. DOI: 10.1016/j.ygyno.2011.06.025. View

13.

Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Warlam-Rodenhuis C . Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355(9213):1404-11. DOI: 10.1016/s0140-6736(00)02139-5. View

14.

Nout R, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L, van der Steen-Banasik E . Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009; 27(21):3547-56. DOI: 10.1200/JCO.2008.20.2424. View

15.

Creutzberg C, van Putten W, Warlam-Rodenhuis C, van den Bergh A, De Winter K, Koper P . Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004; 22(7):1234-41. DOI: 10.1200/JCO.2004.08.159. View

16.

Disaia P, Creasman W, BORONOW R, Blessing J . Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985; 151(8):1009-15. DOI: 10.1016/0002-9378(85)90371-0. View

17.

Creasman W, Odicino F, Maisonneuve P, Quinn M, Beller U, Benedet J . Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S105-43. DOI: 10.1016/S0020-7292(06)60031-3. View

18.

McCloskey S, Tchabo N, Malhotra H, Odunsi K, Rodabaugh K, Singhal P . Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol. 2009; 116(3):404-7. DOI: 10.1016/j.ygyno.2009.06.027. View

19.

Rasool N, Fader A, Seamon L, Neubauer N, Abu Shahin F, Alexander H . Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2009; 116(1):10-4. DOI: 10.1016/j.ygyno.2009.10.043. View

20.

Lin L, Grigsby P, Powell M, Mutch D . Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys. 2005; 63(2):500-4. DOI: 10.1016/j.ijrobp.2005.02.004. View